Translational and Regulatory Sciences
Online ISSN : 2434-4974
Infectious Disease
Development of intranasal Sendai virus vector-based vaccine against COVID-19
Ryutaro SHIMAZAKIKohji KUSANO
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML

2021 Volume 3 Issue 3 Pages 122-124

Details
Abstract

Sendai virus (SeV) vectors are able to infect a diverse range of cells. They have a high affinity for epithelial cells in the respiratory tract, which provides advantageous properties for intranasal inoculation. Vaccination of the respiratory tract, the main route of infection for Coronavirus (COVID-19), can strongly induce mucosal immunity, which is difficult to induce through injected vaccines, in addition to systemic immunity in a manner similar to innate immunity. A SeV vector vaccine carrying part of the SARS-CoV-2 spike-protein gene showed high immunogenicity in pharmacological studies using intranasally inoculated rodents and is a promising next-generation vaccine.

Content from these authors
© 2021 Catalyst Unit

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article
feedback
Top